ReviewThe European respiratory journal2024
Bronchiectasis management in adults: state of the art and future directions.
Review in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The European respiratory society guideline for adult bronchiectasis 2025: summary and implementation guide for primary care.NPJ primary care respiratory medicine · 2026Guideline
- Efficacy and safety of DPP-1 inhibitors in bronchiectasis: a GRADE-assessed meta-analysis of randomized controlled trials.Respiratory research · 2025Pooled it
- Endotypes ofAmerican journal of respiratory and critical care medicine · 2025Trial
- Post-Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management.MedComm · 2026Review
- Efficacy and Safety of Brensocatib in Participants of Asian Race with Non-cystic Fibrosis Bronchiectasis: A Subgroup Analysis of the ASPEN Trial.Pulmonary therapy · 2026Article
- Blood DNA methylation profile is altered in severe bronchiectasis.ERJ open research · 2026Article
- Sputum cathepsin G activity predicts exacerbations and hospitalisations in bronchiectasis.ERJ open research · 2026Article
- Airway Clearance and Pediatric Pulmonary Rehabilitation in Primary Ciliary Dyskinesia: A Clinical Framework for Children and Adolescents.Journal of clinical medicine · 2026Review
- Bronchiectasis in renal transplant patients: a narrative review.BMJ open respiratory research · 2026Review
- An interpretable prognostic model for early unfavorable outcomes after bronchiectasis surgery.BMC pulmonary medicine · 2026Article
- Type 2 inflammation, bronchiectasis and clinical trials: expanding from MAHALE.ERJ open research · 2026Article
- Assessment of a bacterial quantification assay to detect and monitorERJ open research · 2026Article
- Benralizumab in bronchiectasis: results from the phase 3 MAHALE study.ERJ open research · 2026Article
- Incidence and disease burden of bronchiectasis in systemic lupus erythematosus: a nationwide population-based study in Korea.RMD open · 2026Article
- Bronchiectasis in Italy: an analysis of the EMBARC registry.ERJ open research · 2026Article
- Airway clearance management for bronchiectasis in China: a multicentre cross-sectional study from the Chinese bronchiectasis registry (BE-China).The Lancet regional health. Western Pacific · 2026Article
- Clinical Outcome Prediction by High-Resolution Computed Tomography and Echocardiography Assessment of Pulmonary Hypertension in Patients with Bronchiectasis.Tuberculosis and respiratory diseases · 2026Article
- The European Respiratory Society guideline for management of adult bronchiectasis: clinical summary.Breathe (Sheffield, England) · 2026Review
- Effect of transientERJ open research · 2026Article
- Clinical profile and in-hospital outcomes of patients hospitalised for bronchiectasis exacerbation.ERJ open research · 2026Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Formerly regarded as a rare disease, bronchiectasis is increasingly recognised. A renewed interest in this disease has led to significant progress in bronchiectasis research. Randomised clinical trials (RCTs) have demonstrated the benefits of airway clearance techniques, inhaled antibiotics and long-term macrolide therapy in bronchiectasis patients. However, the heterogeneity of bronchiectasis remains one of the most challenging aspects of management. Phenotypes and endotypes of bronchiectasis have been identified to help find "treatable traits" and partially overcome disease complexity. The goals of therapy for bronchiectasis are to reduce the symptom burden, improve quality of life, reduce exacerbations and prevent disease progression. We review the pharmacological and non-pharmacological treatments that can improve mucociliary clearance, reduce airway inflammation and tackle airway infection, the key pathophysiological features of bronchiectasis. There are also promising treatments in development for the management of bronchiectasis, including novel anti-inflammatory therapies. This review provides a critical update on the management of bronchiectasis focusing on treatable traits and recent RCTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.